J. Fernández-Calvo

发表

Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma

J. Miguel, J. S. San Miguel, J. Bladé, 2004, British journal of haematology.

Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients

Marcos González, J. Miguel, A. Órfão, 1997 .

Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma

A. Órfão, J. S. San Miguel, N. Gutiérrez, 2008, British journal of haematology.

Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.

A. Órfão, J. S. San Miguel, M. González, 1997, Blood.

Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.

M. Tormo, J. Hernández-Rivas, A. Oriol, 2002, Haematologica.

Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival

Marcos González, A. Órfão, E. Ocio, 2002, British journal of haematology.

FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.

Marcos González, J. Miguel, R. García-Sanz, 2004, The hematology journal : the official journal of the European Haematology Association.

Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone.

Marcos González, A. Órfão, Jesús M. Hernández, 2003, Blood.

lymphoproliferative disorders with more than one B-cell clone Incidence and clinicobiologic characteristics of leukemic B-cell chronic

Marcos González, J. Miguel, Jesús M. Hernández, 2011 .

Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.

A. Órfão, M. Sanz, J. Pérez-Simón, 1999, Blood.

Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes.

J. Miguel, A. Órfão, J. S. San Miguel, 1998, Blood.

Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti‐tumour effect

Marcos González, A. Órfão, J. S. San Miguel, 2002, British journal of haematology.

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

J. S. San Miguel, J. Ribera, J. Bladé, 2005, Blood.

Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients

J. Miguel, A. Órfão, J. S. San Miguel, 2004, International journal of cancer.

Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.

A. Órfão, N. Gutiérrez, M. D. del Cañizo, 2003, Blood.

Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia.

A. Órfão, N. Puig, B. Paiva, 2011, Clinical lymphoma, myeloma & leukemia.

Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.

A. Órfão, J. S. San Miguel, M. Sánchez, 2003, Cancer.

Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.

A. Órfão, J. S. San Miguel, J. Bladé, 2002, Blood.

Central Nervous System (CNS) Relapse in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Frequency and Prognosis in 467 Patients without Cranial Irradiation for CNS Prophylaxis.

J. Sancho, J. Hernández-Rivas, M. Terol, 2005 .

Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.

J. Esteve, E. Montserrat, J. Garcia-conde, 2001, The hematology journal : the official journal of the European Haematology Association.

Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.

A. Órfão, N. Gutiérrez, M. D. del Cañizo, 2003, Blood.

Minimal residual disease in adolescent ( older than 14 years ) and adult acute lymphoblastic leukemias : early immunophenotypic evaluation has high clinical value

Norma Gutiérrez, Paulo Lucio, Alberto Orfao, 2003 .

and Cytogenetic Characteristics Primary Plasma Cell Leukemia: Clinical, Immunophenotypic, DNA Ploidy,

A. Órfão, M. González, J. Bladé, 2013 .

Characterization of aberrant phenotypes in acute myeloblastic leukemia

J. Miguel, A. Órfão, M. González, 1995, Annals of Hematology.